Evaluation of the immunogenicity and efficacy of a chimeric OMP25–OMP31 antigen in BALB/c mice

Abstract

Abstract Brucellosis is a zoonotic disease causes by Brucella bacteria. So far, there is not any efficient treatment for this infectious disease in animals, although subunit vaccines can be a safe alternative. To this aim, we have designed a new chimeric OMP25‐OMP31 antigen formulated in Chitosan nanoparticles and studied its protective efficiency in vivo. OMP25–OMP31 was produced using spliced overlap extension by polymerase chain reaction and the 3D protein structure and antigenic ability were predicted using computational tools. In addition, the humoural and cellular immune responses were measured by ELISA in six different experimental groups. The immune response showed chimeric rOMP25–OMP31 antigen‐induced higher titers of IFN‐γ and TNF‐α cytokines, while the lowest amount of IL‐4 was dedicated to itself. Also, rOMP25–OMP31 stimulated higher titer of IgG than individual injection of rOMP25 and rOMP31 treatments and the cell proliferation assay demonstrated the vaccination with rOMP25–OMP31 elicits a vigorous antigen‐specific cell proliferative. In addition, the challenge experiment showed immunised mic stimulated a higher level of protection than negative controls. Overall, the results of rOMP25–OMP31 could be promising for considering chimeric constructs as a feasible vaccine candidate for further investigations against brucellosis.

Keywords

• antigenicity
• Brucella
• Brucellosis
• OMP25
• OMP31